CD8A and neoplasm: Notably, tumor derived expression of CXCL10 has been hypothesized to localize effector CD8 + T cells via their CXCR3 receptor to the tumor site, an interaction observed within our RDI network that exhibits anti-tumor properties and is associated with immunotherapy response24,25.